Table 2.
Metabolites controlled by IBD genetic risk variants.
| Analyte | DEM endpoints (10% FDR) | Estimated effect of the IBD risk allele | ||||
|---|---|---|---|---|---|---|
| Serum | Stool | Beta | SE | P value | R2 | |
| locus (hg19): 5:96198479; rsID (prot/risk allele): rs2927614 (C/G); risk allele frequency: 0.78; mapped genes: CAST, ERAP1 | ||||||
| Fibrinopeptide A (3–15) | +CD_vs_UC, +log2SESCD, +Mayo_endo | 0.49 | 0.063 | 3.24E-14 | 7.8% | |
| locus: 6:31709045; rsID (prot/risk allele): rs28381349 (C/T); risk allele frequency: 0.07; mapped genes: ABHD16A, AGER, AIF1, ATF6B, BAG6, C2, C6orf10, C6orf25, CLIC1, CSNK2B, CYP21A1P, CYP21A2, DDAH2, EHMT2, FKBPL, GPANK1, LY6G6C, LY6G6E, LY6G6F, MSH5, MSH5-SAPCD1, NCR3, NOTCH4, PPT2-EGFL8, PRRC2A, PRRT1, RNF5P1, SAPCD1-AS1, SKIV2L, SLC44A4, STK19, TNXB, VARS, VWA7 | ||||||
| X - 11470 | −log2SESCD | −0.75 | 0.100 | 1.47E-13 | 7.4% | |
| locus (hg19): 11:61564299; rsID (prot/risk allele): rs4246215 (G/T); risk allele frequency: 0.32; mapped genes: FADS1, FADS2 | ||||||
| 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)* | −CD, −IBD, −UC | −0.52 | 0.052 | 3.79E-22 | 12.3% | |
| 1,2-dilinoleoyl-GPC (18:2/18:2) | −log2SESCD | 0.37 | 0.054 | 1.65E-11 | 6.2% | |
| 1-arachidonoyl-GPC* (20:4)* | −IBD, −UC | −0.48 | 0.053 | 1.91E-18 | 10.2% | |
| 1-linoleoyl-GPE (18:2)* | 0.39 | 0.054 | 1.93E-12 | 6.7% | ||
| 1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) | −CD, −IBD, −log2SCCAI, −UC | +log2SCCAI | −0.49 | 0.053 | 2.89E-19 | 10.7% |
| 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) | −CD, −IBD, −log2SCCAI, −UC | −0.62 | 0.051 | 1.10E-31 | 17.6% | |
| docosatrienoate (22:3n6)* | −CD, −IBD | −0.35 | 0.054 | 2.75E-10 | 5.5% | |
| oleoyl-arachidonoyl-glycerol (18:1/20:4) [1]* | +CD_vs_UC, −IBD, −UC | −0.34 | 0.054 | 9.62E-10 | 5.1% | |
| oleoyl-arachidonoyl-glycerol (18:1/20:4) [2]* | −CD, +CD_vs_UC, −IBD, −UC | +CD, +IBD, +log2SCCAI, +log2SESCD, +Mayo_endo, +UC | −0.32 | 0.054 | 4.43E-09 | 4.7% |
| stearoyl-arachidonoyl-glycerol (18:0/20:4) [1]* | −UC | −0.38 | 0.054 | 3.75E-12 | 6.6% | |
| 1-oleoyl-2-linoleoyl-GPE (18:1/18:2)* | +log2HBI | 0.34 | 0.054 | 1.03E-09 | 5.1% | |
| 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) | +CD_vs_UC, +log2HBI | 0.38 | 0.054 | 5.36E-12 | 6.5% | |
| 1-stearoyl-2-linoleoyl-GPE (18:0/18:2)* | +CD_vs_UC, +log2HBI | 0.37 | 0.054 | 1.86E-11 | 6.2% | |
| locus (hg19): 14:67976325; rsID (prot/risk allele): rs386778467 (T/C); risk allele frequency: 0.49; mapped genes: PLEKHH1, TMEM229B | ||||||
| 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* | −CD_vs_UC, −log2HBI, −log2SESCD | 0.44 | 0.050 | 5.78E-18 | 10.0% | |
| 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* | −CD, −IBD, −log2HBI, −log2SESCD | +IBD, +log2SCCAI, +log2SESCD, +Mayo_endo, +UC | 0.46 | 0.050 | 2.22E-19 | 10.8% |